Magenta to explore targeted gene editing to cure HIV

By The Science Advisory Board staff writers

September 3, 2020 -- Clinical-stage biotechnology company Magenta Therapeutics has joined a broad-based research effort to explore gene- and cell-based approaches to cure HIV.

The U.S. National Institutes of Health (NIH) awarded the group a five-year, $14.9 million U19 grant to advance the research into hematopoietic stem and progenitor cell (HSPC) engineering and transplantation with the goal of complete HIV-1 infection remission.

As part of the program, Magenta will optimize cell dose in animal models and determine whether HSPC transplant results in disease control. The project includes researchers studying gene editing, HIV, and stem cell transplantation at a number of premier institutions, including the University of Southern California, the University of Washington, and Harvard University.

NIH establishes Centers for Research in Emerging Infectious Diseases
The National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH), has awarded 11 grants for a first-year...
NIH launches clinical trial for COVID-19 antibody treatment
The National Institutes of Health (NIH) has started enrolling volunteers in a phase III randomized, controlled clinical trial to test multiple monoclonal...
Modified CRISPR system aims to improve therapies for HIV, sickle cell disease
Researchers from City of Hope have improved the CRISPR-Cas9 system through novel sequence changes to the trans-activating RNA (tracrRNA). The improved...
NIH Invests $100 million in cures for sickle cell disease and HIV
The National Institutes of Health (HIH) announced that it plans to invest at least $100 million over the next four years towards developing affordable,...
High Performance Liquid Chromatography: A Growing Technology Driven by Pharmacology
Vaccines strengthen our immune systems by exposing white blood cells to disease-specific antigens. This builds a depot of memory T cells, so in the case...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter